"Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
John W JacksonLisa FulchinoJames RogersHelen MogunJennifer PolinskiDavid C HendersonSebastian SchneeweissMichael A FischerPublished in: Pharmacoepidemiology and drug safety (2017)
PA policies may represent a major treatment barrier for risperidone LAI among relapsed patients. Non-adherence plays a little role in predicting which patients receive LAIs. Policy makers and health insurers will need to consider these findings when guiding the use of LAIs. KEY POINTS Among a nationwide cohort of relapsed schizophrenia patients enrolled in US Medicaid, 3.1% received Risperdal Consta, a long-acting injectable antipsychotic (LAI), and 3.8% initiated a first-generation first-generation LAI within 90 days after discharge. During 2004 to 2006, there was marked variation in 90 day post-relapse initiation of Risperdal-Consta-a newly marketed medication during this period-and also marked variation in 90 day post-relapse initiation of any first-generation LAI, which appeared to be associated with race/ethnicity and geography. Prior authorization policies were associated with substantially lower initiation of Risperdal Consta in this cohort of relapsed patients even after accounting for clinical indication (non-adherence), relapse history, demographics, adjunctive medication, and mental health service use.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- healthcare
- acute lymphoblastic leukemia
- prognostic factors
- acute myeloid leukemia
- peritoneal dialysis
- emergency department
- bipolar disorder
- metabolic syndrome
- adipose tissue
- patient reported outcomes
- hodgkin lymphoma
- insulin resistance
- multiple myeloma
- health insurance
- skeletal muscle
- adverse drug
- electronic health record
- social media